Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study.

Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y, Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben Yakar R, Rowe JM.

Blood Adv. 2019 Nov 26;3(22):3740-3749. doi: 10.1182/bloodadvances.2019000468.

2.

Association between inflammatory back pain features, acute and structural sacroiliitis on MRI, and the diagnosis of spondyloarthritis.

Kivity S, Gofrit SG, Baker FA, Leibushor N, Tavor S, Lidar M, Eshed I.

Clin Rheumatol. 2019 Jun;38(6):1579-1585. doi: 10.1007/s10067-019-04432-5. Epub 2019 Jan 10.

PMID:
30628016
3.

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.

Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjamini O, Nagler A, Pereg Y, Tavor S, Peled A.

Leukemia. 2017 Nov;31(11):2336-2346. doi: 10.1038/leu.2017.82. Epub 2017 Mar 10.

PMID:
28280274
4.

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C.

Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12.

5.

The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.

Williams MT, Yousafzai YM, Elder A, Rehe K, Bomken S, Frishman-Levy L, Tavor S, Sinclair P, Dormon K, Masic D, Perry T, Weston VJ, Kearns P, Blair H, Russell LJ, Heidenreich O, Irving JA, Izraeli S, Vormoor J, Graham GJ, Halsey C.

Blood. 2016 Apr 21;127(16):1998-2006. doi: 10.1182/blood-2015-08-665034. Epub 2016 Feb 11.

PMID:
26869395
6.

Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.

Ellis MH, Lavi N, Mishchenko E, Dally N, Lavie D, Courevitch A, Gutwein O, Bulvik S, Braester A, Chubar E, Tavor S, Duek A, Kirgner I, Koren-Michowitz M.

Leuk Res. 2015 Aug 12. pii: S0145-2126(15)30356-8. doi: 10.1016/j.leukres.2015.08.003. [Epub ahead of print]

PMID:
26364797
7.

Role of CXCR4 in the pathogenesis of acute myeloid leukemia.

Peled A, Tavor S.

Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Review.

8.

High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.

Tavor S, Rahamim E, Sarid N, Rozovski U, Gibstein L, Aviv F, Kirsner I, Naparstek E.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):438-43. doi: 10.1016/j.clml.2012.05.007. Epub 2012 Sep 25.

PMID:
23017331
9.

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?

Barak AF, Bonstein L, Lauterbach R, Naparstek E, Tavor S.

Hematol Rep. 2011 Oct 19;3(3):e29. doi: 10.4081/hr.2011.e29. Epub 2011 Dec 6.

10.

Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia.

Tavor S, Rothman R, Golan T, Voskoboinik N, Katz BZ, Sarid N, Shomrat R, Orr-Urtreger A, Naparstek E.

Leuk Lymphoma. 2011 Apr;52(4):642-7. doi: 10.3109/10428194.2010.551571. Epub 2011 Feb 16.

PMID:
21323513
11.

Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?

Tavor S, Petit I.

Semin Cancer Biol. 2010 Jun;20(3):178-85. doi: 10.1016/j.semcancer.2010.07.001. Epub 2010 Jul 15. Review.

PMID:
20637871
12.

The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?

Katz BZ, Tavor S.

Leuk Lymphoma. 2009 Jul;50(7):1067-8. doi: 10.1080/10428190902991837. No abstract available.

PMID:
19557626
13.

Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.

Dezorella N, Pevsner-Fischer M, Deutsch V, Kay S, Baron S, Stern R, Tavor S, Nagler A, Naparstek E, Zipori D, Katz BZ.

Exp Cell Res. 2009 Jul 1;315(11):1904-13. doi: 10.1016/j.yexcr.2009.03.016. Epub 2009 Mar 27.

PMID:
19328780
14.

Engraftment of human blood malignancies to the turkey embryo: a robust new in vivo model.

Grinberg I, Reis A, Ohana A, Taizi M, Cipok M, Tavor S, Rund D, Deutsch VR, Goldstein RS.

Leuk Res. 2009 Oct;33(10):1417-26. doi: 10.1016/j.leukres.2009.02.009. Epub 2009 Mar 17.

PMID:
19297019
15.

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.

Tavor S, Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Benzion K, Kay S, Baron S, Amariglio N, Deutsch V, Naparstek E, Rechavi G.

Leukemia. 2008 Dec;22(12):2151-5158. doi: 10.1038/leu.2008.238. Epub 2008 Sep 4.

PMID:
18769446
16.

Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells.

Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, Goichberg P, Tesio M, Netzer N, Naparstek E, Hardan I, Nagler A, Resnick I, Tsimanis A, Lapidot T.

Cancer Res. 2006 Nov 15;66(22):11013-20.

17.

Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.

Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D.

Leukemia. 2006 Dec;20(12):2147-54. Epub 2006 Oct 12.

PMID:
17039238
18.

Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice.

Tavor S, Petit I, Porozov S, Goichberg P, Avigdor A, Sagiv S, Nagler A, Naparstek E, Lapidot T.

Blood. 2005 Sep 15;106(6):2120-7. Epub 2005 Jun 7.

PMID:
15941909
19.

Correlation between CXCR4 and homing or engraftment of acute myelogenous leukemia.

Monaco G, Belmont JW, Konopleva M, Andreeff M, Tavor S, Petit I, Kollet O, Lapidot T.

Cancer Res. 2004 Sep 15;64(18):6832 author reply 6832-3. No abstract available.

20.

CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.

Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T.

Cancer Res. 2004 Apr 15;64(8):2817-24.

Supplemental Content

Support Center